Drug Trial Radar · NCT06672237
A Phase 3 Study of NTLA-2001 in ATTRv-PN
Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
67
Actual
Start
Nov 22, 2024
Primary completion
Jul 2027
Study completion Aug 2028
Sponsor
- Lead sponsor
- Intellia TherapeuticsIndustry
- Sponsor type
- Industry
- Collaborators
- Regeneron Pharmaceuticals
- First posted
- Nov 4, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will be conducted to evaluate the efficacy and safety of a single dose of nexiguran ziclumeran (NTLA-2001) compared to placebo in participants with ATTRv-PN.
Conditions
- Neuromuscular Disease
- Neuromuscular Diseases (NMD)
- Neurodegenerative Disease
- Neurodegenerative Disease, Hereditary
- Neurodegenerative Diseases
- Neuromuscular Diseases
- Nerve Disorders
- Nervous System Disease
- Nervous System Diseases
- Genetic Disease, Inborn
- Amyloidosis, Familial
- Amyloidosis, Hereditary
- Amyloidosis
- Polyneuropathies
- Amyloid Neuropathies
- Amyloid Neuropathies, Familial
- Peripheral Nervous System Disease
- Peripheral Nervous System Diseases
- Metabolism, Inborn Errors
- Metabolic Diseases
Interventions
nexiguran ziclumeranBiological
nexiguran ziclumeran 55 mg by single IV infusion
Normal Saline as PlaceboDrug
Normal saline (0.9% NaCl) by single IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Modified Neuropathy Impairment Score +7 (mNIS+7)Time frame: 18 Months
- Serum TTRTime frame: 29 Days
Locations
14 sites in 6 countries. Site status is shown where the registry gives one.
Hospital Británico de Buenos Aires
Buenos Aires, Argentina
Hospital Italiano de Buenos Aires (HIBA)
Buenos Aires, Argentina
Hospital El Cruce
San Juan Bautista, Argentina
Hospital das Clinicas da Universidade Estadual de Campinas (UNICAMP)
Campinas, Brazil
HCFMRP - Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto
Ribeirão Preto, Brazil
Instituto de Educacao, Pesquisa e Gestao em Saude
Rio de Janeiro, Brazil
PSEG Centro de Pesquisa Clinica S.A.
São Paulo, Brazil
National Institute of Medical Sciences and Nutrition - Salvador Zubiran (INCMNSZ)
Tlalpan, Mexico
National University Hospital
Singapore, Singapore
Singapore General Hospital
Singapore, Singapore
National Taiwan University Hospital
Taipei, Taiwan
Taipei Veterans General Hospital
Taipei, Taiwan
Chang Gung Medical Foundation - Linkou Branch
Taoyuan, Taiwan
Siriraj Hospital
Bangkok, Thailand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.